Small molecule · Oncology
AR-101
Oral kinase inhibitorPlaceholder
A selective, orally available inhibitor designed against a kinase whose over-activity drives a subset of solid tumours with limited treatment options.
Development stage
- Discovery
- Lead optimisation
- Preclinical
- Clinical
Scientific rationale
- Target nominated by the evidence engine from tumour transcriptomics and genetic-dependency data.
- Generative design prioritised selectivity over the closest kinome neighbours from the first design cycle.
- Lead series shows on-target activity in cellular assays; in vivo efficacy and safety studies are under way.